• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Scienture Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    10/3/25 4:50:37 PM ET
    $SCNX
    Other Pharmaceuticals
    Health Care
    Get the next $SCNX alert in real time by email
    false 0001382574 0001382574 2025-10-03 2025-10-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 OR 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): October 3, 2025

     

    Scienture Holdings, Inc.

    (Exact Name of Registrant as Specified in Its Charter)

     

    Delaware   001-39199   46-3673928

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File No.)

     

    (I.R.S. Employer

    Identification No.)

     

    20 Austin Blvd.

    Commack, NY 11725

    (Address of Principal Executive Offices)

     

    (631) 670-6039

    (Registrant’s Telephone Number)

     

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.00001 per share   SCNX   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01. Entry into a Material Definitive Agreement.

     

    As previously disclosed, Scienture Holdings, Inc. (the “Company”) issued 10% original issue discount secured convertible debentures (the “Debentures”) to Arena Finance Markets, LP and Arena Special Opportunities III LP (the “Arena Investors”) on November 25, 2024.

     

    On October 3, 2025, the Company entered into a letter agreement (the “Agreement”) with the Arena Investors whereby the Company and the Arena Investors agreed to amend Section 4(b) of the Debentures. Specifically, the Company and the Arena Investors agreed to revise the conversion price of the Debentures to $2.4861 per share. In addition, each of the Arena Investors agreed to convert the remaining amounts owed by the Company under the Debentures into shares of the Company’s common stock, par value $0.00001 per share (the “Common Stock”) in accordance with the revised terms of the Debentures (the “Full Conversion”).

     

    Pursuant to the Agreement, upon the Full Conversion, automatically and without any further action on the part of the Company or the Arena Investors: (i) all Obligations (as defined in the Security Agreement dated November 25, 2024, by and among the Company and the Arena Investors) under the Transaction Documents (as defined in the Securities Purchase Agreement dated November 22, 2024, by and among the Company and the Arena Investors (the “Purchase Agreement”)) will be deemed paid and will be automatically and irrevocably released, satisfied and discharged in full (except those obligations of the Company under Section 5.10 of the Purchase Agreement and Section 7 of the Registration Rights Agreement dated November 25, 2024, by and among the Company and the Arena Investors); (ii) the Debentures and all other Transaction Documents will be terminated; (iii) all security interests, pledges and other liens of every type at any time granted to or held by the Arena Investors as security for the Obligations or under any Transaction Document will be terminated and automatically and irrevocably released without further action by the Arena Investors; and (iv) neither of the Arena Investors will have any obligation to make any credit extensions or financial accommodations to the Company or any other obligations, duties, or responsibilities in connection therewith.

     

    The foregoing description of the Agreement is qualified in its entirety by reference to the full text of the Agreement, a copy of which is attached hereto as Exhibit 10.1, and which is incorporated herein in its entirety by reference.

     

    Item 9.01. Financial Statements and Exhibits.

     

    Exhibit No.   Description
    10.1   Letter Agreement dated October 2, 2025, by and among the Company, Arena Finance Markets, LP, and Arena Special Opportunities III LP
    104   Cover Page Interactive Data File (embedded with the Inline XBRL document).

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      SCIENTURE HOLDINGS, INC.
         
      By: /s/ Dr. Narasimhan Mani
        Dr. Narasimhan Mani
        Co-Chief Executive Officer
         
    Date: October 3, 2025    

     

     

     

     

    Get the next $SCNX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SCNX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SCNX
    SEC Filings

    View All

    Scienture Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Scienture Holdings, Inc. (0001382574) (Filer)

    10/3/25 4:50:37 PM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    Scienture Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Scienture Holdings, Inc. (0001382574) (Filer)

    9/23/25 5:01:18 PM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    SEC Form 424B5 filed by Scienture Holdings Inc.

    424B5 - Scienture Holdings, Inc. (0001382574) (Filer)

    9/19/25 5:15:16 PM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    $SCNX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SCIENTURE Secures Multiple Commercial GPO Agreements, Expanding U.S. Market Access for Arbli™ (losartan potassium) to more than 2500 Healthcare Institutions

    Represents potential penetration into ~ 20% of the U.S. institutional market, while broadening access across long-term care and outpatient facilities U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunity for Arbli™ as the first FDA-approved ready-to-use oral suspension COMMACK, NY, Oct. 01, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced

    10/1/25 9:00:00 AM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market

    Arbli™ is the first and only ready-to-use liquid formulation of losartan, eliminating the need for compounding while offering reduced dosing volume and extended room-temperature shelf life COMMACK, NY, Sept. 16, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that it has formalized a major commercial Pharmacy Benefit Manager (PBM) led Group Purchasing Organization (GPO) rebate agreement

    9/16/25 8:05:00 AM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    Scienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common Stock

    Commack, NY, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Scienture Holdings, Inc. (NASDAQ:SCNX) ("Scienture" or the "Company"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase 3,225,000 shares of common stock at an offering price of $1.20 per share, in a registered direct offering. The gross proceeds for the offering are expected to be approximately $3.9 million bef

    8/14/25 9:00:00 AM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    $SCNX
    Leadership Updates

    Live Leadership Updates

    View All

    SCIENTURE Announces Executive Leadership Transition

    TAMPA, FL, May 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) (the "Company"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that Suren Ajjarapu, who has served as Chief Executive Officer (CEO) and Chairman of the Board of Directors (BOD), has stepped down from his roles with the Company, with those positions being assumed by the existing, experienced management team of Dr. Shankar Hariharan and Dr. Narasimhan Mani. Shankar Hariharan, P

    5/22/25 8:05:00 AM ET
    $SCNX
    Other Pharmaceuticals
    Health Care